on ABIVAX (EPA:ABVX)
Abivax: Annual General Meeting scheduled for May 11, 2026
The biotechnology company Abivax has announced that its Annual General Meeting and Extraordinary General Meeting will be held on May 11, 2026, at the Paris Marriott Opera Ambassador Hotel. This meeting will provide shareholders with an opportunity to review the agenda and draft resolutions published in the BALO (Bulletin des Annonces Légales Obligatoires) in early April 2026.
The documents required for this meeting are accessible in accordance with applicable legal regulations, notably via the official Abivax website. This company, specializing in the development of innovative therapies for chronic inflammatory diseases, continues its research on its lead drug candidate, Obefazimod, currently in phase 3 clinical trials.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news